Showing 20 of 107 recruiting trials for “acute-leukemia-of-ambiguous-lineage”
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
👨⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
👨⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06377579 ↗
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
👨⚕️ Pierre PETERLIN, Dr, French Innovative Leukemia Organisation📍 21 sites📅 Started Jul 2024View details ↗
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
👨⚕️ Ann Dahlberg, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Jul 2024View details ↗
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
👨⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
A Study of GLB-001 in Patients With Myeloid Malignancies
👨⚕️ Gang Lu, Ph.D., Hangzhou GluBio Pharmaceutical Co., Ltd.📍 14 sites📅 Started May 2024View details ↗
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
👨⚕️ Amber Afzal, M.D., MSCI, Washington University School of Medicine📍 1 site📅 Started Feb 2024View details ↗
Cladribine Venetoclax in Monocytic AML
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
RecruitingNCT06116318 ↗
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Universal CAR-T Cells Targeting AML
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →